Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

GAP Assessment for Waters Empower CSV documentation

A German pharmaceutical company approached Zamann requesting support as they needed technical consultancy to ensure that the CSV documentation related to the Waters Empower system was 100% compliant with the required standards and references. Therefore, we proposed a complete documentation evaluation, considering that this GAP Assessment process would be essential to ensure compliance with FDA regulations and GAMP guidelines. We offered a clear, self-explanatory, robust and holistic assessment of the entire environment surrounding CSV, and expert recommendations for remediation through CAPAs (Corrective and Preventive Actions).

Challenges Faced

A chemist is testing a newly discovered chemical using a variety of scientific equipment in his lab,
  • Regulatory Scrutiny: The client’s computerized system was subject to FDA inspection, and any GAPs in validation documentation could result in significant findings or penalties.
  • Document Volume: The system’s validation documentation was extensive, including validation plans, protocols, testing scripts, and reports.
  • Complexity of Regulations: GAMP and FDA requirements are extensive and complex, requiring a deep understanding of risk-based approaches and lifecycle validation principles.
  • Time Sensitivity: The GAP Assessment needed to be completed within a short time frame to meet internal deadlines for regulatory submissions.

Zamann Pharma Support’s Approach

  • Project Initialization: Conducted an initial kick-off meeting with all related areas, to understand goals, timelines, and specific concerns. Review the current validation lifecycle documentation to map the scope of the GAP assessment.
  • Document Review: Each validation document was analyzed against FDA regulations and GAMP guidelines. Key focus documents including: User Requirements Specifications (URS), Functional Specifications (FS), Validation Master Plan (VMP), Test protocols/reports (IQ, OQ, PQ), Traceability matrices, and Change Control records.
  • Key Topics Evaluated: Risk assessments were compared against GAMP’s emphasis on risk-based validation. Testing protocols were checked for alignment with FDA expectations for data integrity, including audit trails and electronic signatures (21 CFR Part 11). Change management and deviation handling practices were evaluated for consistency and completeness.
  • Structured Findings: Delivered a detailed report with observations categorized into:
  • Critical GAPs: Direct non-conformances with FDA regulations or GAMP5 principles.
  • Major GAPs: Areas that could lead to regulatory observations if not addressed.
  • Minor GAPs: Opportunities to enhance documentation quality and robustness.
  • Corrective and Preventive Actions proposal: For each potential GAP, specific CAPAs were proposed, including: Revision of URS and FS to better reflect user needs and risk assessments. Updates to test protocols to ensure comprehensive testing of audit trails and electronic signature functionalities. Enhancements to traceability matrices to demonstrate complete coverage of user and functional requirements. Implementation of additional training for staff on validation principles and documentation practices. Update of some document templates, to facilitate their routine use, as well as the understanding of auditors.
  • Support for Implementation: Provided templates and examples to guide document revisions. Conducted workshops with the client’s team to ensure a clear understanding of CAPA execution. Establishment of a follow-up system to track CAPA progress.

Results Achieved

  • Regulatory Compliance: The GAP Assessment and proposed CAPAs brought the client’s validation documentation in line with FDA and GAMP5 requirements.
  • Improved Documentation: The client’s documentation was streamlined, making it easier to manage, review, and present during inspections.
  • Risk Mitigation: Identifying and addressing critical GAPs reduced the risk of regulatory findings or penalties.
  • Team Empowerment: By involving the client’s team in workshops and CAPA planning, they gained a deeper understanding of validation best practices and regulatory expectations.
  • Timely Completion: The assessment and remediation plan were completed on schedule, ensuring the client could meet their internal deadlines.
Laboratory

Client Testimonial

“Zamann Pharma Support’s expertise in regulatory compliance and GAMP5 was invaluable. Their thorough and structured GAP Assessment gave us confidence in the robustness of our validation documentation. Their practical and actionable CAPA proposals made the remediation process seamless and effective. We’re now fully prepared for any regulatory inspection.”

Contact Us

Need help? Don't hesitate to get in touch
Zamann pharma support is committed to protecting and respecting your privacy, and we’ll use your personal information to administer your account and to provide the products and services you requested from us.